



From genetics, health

Acquisition and platform update

09 | 07 | 21



Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the company's beliefs regarding its business and business strategy; and the benefits and importance of the company's acquisitions and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the closing of the pending acquisition of Ciitizen; the ability of the company to achieve the expected benefits of the acquisition; the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the ability to maintain important customer relationships; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to obtain regulatory approval for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; the applicability of clinical research results to actual outcomes; the success of collaborations; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.



Single greatest shift in medicine and healthcare

“Modern” medicine

Chemotherapy standard of care

Newborn diagnosis after birth

Symptom-based, universally applied

Universal testing for all

Risk information = effective prevention

Earliest detection – disease eradication

Personalized therapy and biomarker driven monitoring

Gene informed healthcare throughout life



Invitae's mission and core data tenets



Patients own
their health
data

Health data
is more
valuable
when shared

A patient-mediated platform for data sharing



A **patient-mediated** platform that allows patients to collect and store their medical records, and **turns documents into usable, computable** and relevant **longitudinal data** that can be shared with whomever they consent



SECTION 32



Data with a purpose – Ciitizen's founding story



Anil Sethi

Founder of Glimpse, acquired by
Apple in 2016



Ciitizen Muse – Tania

Founded Ciitizen following the
death of his sister, Tania, who
battled metastatic breast cancer



Challenges within the current system



Fragmented &
non-standard data



"Dark data",
limited by FHIR



Onerous to
access my data



Perceived risk
to privacy



How it works

Step 1: Collect all medical documents



- Onboard to Ciitizen
- Consent to share data



- Use patient's HIPAA right of access-to-access raw records
- Ciitizen obtains all, unstructured records



- Medical records and images uploaded to patient's account



How it works (con't)

Step 2: Convert documents into useful data



- AI/machine learning extraction
- Defined data elements





- Human assisted quality review





- Patients own their data and can easily share records and images with any provider or person





One Company. One Patient. All patients



Trust is the Foundation of our Strategy

Patients own and control their data



Consent & preferences

Security

Privacy


Transparency of usage

Usefulness to the patient and society

Accuracy



Patient-centered data will drive the molecular medicine era*



Data/platform and information flow*

Inputs/ Patient Data



Genomic profiles



Historical procedures



Family history/lifestyle



EMR sources



Biometric/wearables



Patient surveys



Imaging records



Pharmacy



Personal Digital
Health Wallet



Outputs/ Patient Benefits



Decision support



Trial matching



Clinical trial access



Real-world data



Outcomes data



Advocacy



Reimbursement support



Opening up to a variety of partnerships and ecosystem players



Patient Advocacy Groups



Biopharma/Testing



Healthcare Provider Networks



Payor Ecosystem



Pharmacy/Retail Health



Telemedicine Networks



Summary transaction terms*

		Summary terms
Upfront Value	Cash	\$125M ⁽¹⁾
	Shares of Invitae common stock	7.07M ⁽²⁾
	Total Upfront Cash and Shares	\$325M
Employee Retention	RSUs for Continuing Employees	\$225M ⁽³⁾

Notes: * Subject to closing

- (1) Subject to adjustment for debt, working capital and transaction expenses
- (2) Consideration paid in shares calculated based on a trailing closing average price
- (3) RSUs vest over time



Bringing genetics into mainstream medicine

GENOME MANAGEMENT

Provide genetic information services that inform healthcare throughout life

Share genetics on a global scale to diagnose more patients correctly, earlier, and bring therapies to market faster

GENOME NETWORK

Make acquisitions that expand test menu content and services to open new markets

GENETIC TESTING

Build partnerships with industry peers to increase utilization of genetic testing

Make genetic testing more affordable and more accessible



Q&A





INVITAE